Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional inte...
Main Authors: | Fatemeh Yavari, Pardis Oliazadeh, Meisam Radfar, Mohsen Foroughipour, Karim Nikkhah, Alireza Heidari Bakavoli, Morteza Saeidi |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2021-03-01
|
Series: | Basic and Clinical Neuroscience |
Subjects: | |
Online Access: | http://bcn.iums.ac.ir/article-1-1412-en.html |
Similar Items
-
Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021-04-01) -
A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
by: Mehrdokht Mazdeh, et al.
Published: (2019-04-01) -
The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
by: Morteza Abdar, et al.
Published: (2017-03-01) -
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
by: Burcu Altunrende, et al.
Published: (2017-12-01) -
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto A, et al.
Published: (2015-12-01)